|Group — equity investments||2013|
|Cost and net book value at 1 May||2,548||1,101|
|Cost and net book value at 30 April||3,650||2,548|
In April 2013, the Group invested a further £1.1m in Atlas Genetics Limited, a UK-based privately owned healthcare technology company with an ultra-rapid point of care (POC) diagnostics platform. The Group's UK division, Bespak, undertakes design for manufacture work to prepare disposable test cards that are a core component of the Atlas system and has also been awarded long-term manufacturing rights for the card.
|Cost and net book value||82,092||83,327|
|Other equity investments|
|Investment in Atlas Genetics Limited||3,650||2,548|
The Company has disposed of its indirect holding in King Systems which had been held at cost of £1,235,000.
|Long-term loans to Group undertakings|
|At 1 May||75,515||60,579|
|Net movement in the year||(29,919)||13,719|
|Effects of exchange rate changes||3,071||1,217|
|Net book value at 30 April||48,667||75,515|
Interest is charged on long-term loans to subsidiaries at rates linked to LIBOR.
A list of the Company's principal subsidiaries is included in note 30.